PDCD1 and neoplasm: Selective inhibition of TGF-β1 combined with anti-PD-1 antibodies elicits robust anti-tumor responses and survival benefit in resistant murine tumor models without cardiotoxicity [113], and similar synergy is seen when pairing TGF-β1 blockade with cancer vaccines [11].